» Articles » PMID: 11211364

Multimodal Treatment of ADHD in the MTA: an Alternative Outcome Analysis

Abstract

Objective: To conduct a post hoc investigation of the utility of a single composite measure of treatment outcome for the NIMH Collaborative Multisite Multimodal Treatment Study of Children With Attention-Deficit/Hyperactivity Disorder (MTA) at 14 months postbaseline.

Background: Examination of multiple measures one at a time in the main MTA intent-to-treat outcome analyses failed to detect a statistically significant advantage of combined treatment (Comb) over medication management (MedMgt). A measure that increases power and precision using a single outcome score may be a useful alternative to multiple outcome measures.

Method: Factor analysis of baseline scores yielded two "source factors" (parent and teacher) and one "instrument factor" (parent-child interactions). A composite score was created from the average of standardized parent and teacher measures.

Results: The composite was internally consistent (alpha = .83), reliable (test-retest over 3 months = 0.86), and correlated 0.61 with clinician global judgments. In an intent-to-treat analysis, Comb was statistically significantly better than all other treatments, with effect sizes ranging from small (0.28) versus MedMgt, to moderately large (0.70) versus a community comparison group.

Conclusions: A composite of ADHD variables may be an important tool in future treatment trials with ADHD and may avoid some of the statistical limitations of multiple measures.

Citing Articles

Hyped-up or meditate: A scoping review of mindfulness-based group interventions for adolescents with attention deficit hyperactivity disorder.

Tan L, Jones M Clin Child Psychol Psychiatry. 2024; 29(4):1383-1399.

PMID: 39118240 PMC: 11484164. DOI: 10.1177/13591045241272835.


Reducing disparities in behavioral health treatment in pediatric primary care: a randomized controlled trial comparing Partnering to Achieve School Success (PASS) to usual ADHD care for children ages 5 to 11 - study protocol.

Mautone J, Holdaway A, Chan W, Michel J, Guevara J, Davis A BMC Prim Care. 2024; 25(1):225.

PMID: 38909215 PMC: 11193903. DOI: 10.1186/s12875-024-02473-7.


ADHD Prevalence Rose, Yet Disparities Remain: Commentary on the 2022 National Survey of Children's Health.

Chronis-Tuscano A, Bounoua N J Clin Child Adolesc Psychol. 2024; 53(3):361-372.

PMID: 38905157 PMC: 11193851. DOI: 10.1080/15374416.2024.2359075.


Benefits of a 12-Week Non-Drug "Brain Fitness Program" for Patients with Attention-Deficit/Hyperactive Disorder, Post-Concussion Syndrome, or Memory Loss.

Fotuhi M, Khorrami N, Raji C J Alzheimers Dis Rep. 2023; 7(1):675-697.

PMID: 37483322 PMC: 10357116. DOI: 10.3233/ADR-220091.


Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Storebo O, Storm M, Ribeiro J, Skoog M, Groth C, Callesen H Cochrane Database Syst Rev. 2023; 3:CD009885.

PMID: 36971690 PMC: 10042435. DOI: 10.1002/14651858.CD009885.pub3.